港股異動 | 中國恆大漲超7%,爲房車寶引入投資者
uSMART盈立智投3月29日消息,週一港股早盤,中國恆大高開高走,截至10:13,中國恆大盤中漲超7%。
週一港股盤前,中國恆大發布公告稱,旗下房車寶引入弘毅投資、中信資本等17名投資者,投資總代價爲163.5億港元。
恆大目前間接持有及控制房車寶約80.8%權益。根據引資安排,目標公司同意向投資方發行合共約6.51億股新股,總認購價爲81.75億港元及賣方同意向投資方出售合共約6.51億股目標公司股份,總出售價爲81.75億港元。
此外,彭博報道稱,中國恆大計劃讓New Gains在納斯達克或其他合適證券交易所掛牌上市。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.